List view / Grid view
30 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced top-line results of its final Phase III clinical study for armodafinil (NUVIGIL®)...
30 August 2013 | By Abbott
Analysis of more than 1 million adult hospital cases revealed 21 percent reduction in length of hospital stay and cost with nutritional intervention...
29 August 2013 | By Daiichi Sankyo
Daiichi Sankyo has filed an application for approval in Japan to manufacture and market RANMARK®...
29 August 2013 | By Sanofi
Sanofi announces that it has successfully priced its offering of EUR 1 billion of notes, due 2020, bearing interest at an annual rate of 1.875%...
28 August 2013 | By IMBA - Institute of Molecular Biotechnology GmbH
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory...
28 August 2013 | By Carbon Trust
ABPI collaborates with the Carbon Trust to help pharmaceutical companies quickly estimate the carbon footprint of tablet medicines distributed in blister packs...
27 August 2013 | By Amgen
Amgen will present new data on omecamtiv mecarbil, a small molecule cardiac myosin activator that is being studied for the treatment of heart failure in collaboration with Cytokinetics...
26 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013...
26 August 2013 | By Sanofi Pasteur
“We are pleased that this study demonstrates the superior relative efficacy of Fluzone High-Dose vaccine..."
26 August 2013 | By Novartis
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp...
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
21 August 2013 | By kdm communications limited
Corresponding with the 60th Anniversary of the Association for Clinical Biochemistry, Abbott recently hosted an enthusiastically received session at the Annual ACB FOCUS National Meeting held in York, entitled The Diamond Generation; Pathology begins at 60...
21 August 2013 | By Abbott
Abbott has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices...
